Clinical Trial Update: Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating rubitecan in cancer patients with renal or hepatic dysfunction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Rubitecan (9-aminocamptothecin)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Tumors | Phase 1 | Status: COMPLETED